The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study

NCT06801977 | Recruiting

• 1 other identifier: SL-B2025-059-01
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 2

Brief Summary

This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.

Conditions

Primary Pulmonary Lymphoepithelioma-like Carcinoma

Keywords

Genome-Wide Association Study; primary Pulmonary Lymphoepithelioma-like Carcinoma

Outcome Measures

Primary Outcomes (1)

• the occurrence of Pulmonary Lymphoepithelioma-like Carcinoma

  pathological diagnosis of Pulmonary Lymphoepithelioma-like Carcinoma

  The enrollment of the participants

Study Arms (2)

SYSUCC cohort, Guangdong, China

Cases: Patients aged 18 and above with a pathological diagnosis of primary pulmonary lymphoepithelioma-like carcinoma who were treated at the Sun Yat-sen University Cancer Center from January 1, 2002. Controls: Healthy participants aged 18 and above.

Genetic: Genome-wide genotyping

Foshan cohort, Guangdong, China

Cases: Patients aged 18 and above with a pathological diagnosis of primary pulmonary lymphoepithelioma-like carcinoma who were treated at the the First People's Hospital of Foshan from January 1, 2007. Controls: Healthy participants aged 18 and above.

Genetic: Genome-wide genotyping

Interventions

Genome-wide genotyping GENETIC

Whole blood from the participants was used to extract DNA for genotyping.

Foshan cohort, Guangdong, China; SYSUCC cohort, Guangdong, China

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population consisted of cases and controls with specific inclusion and exclusion criteria. Cases were individuals pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma (PLELC), excluding those with metastatic nasopharyngeal carcinoma or severe cardiovascular, liver, or kidney disease. Controls were individuals in good physical condition with stable levels of consciousness, excluding those with a history of cancer or severe cardiovascular, liver, or kidney disease.

You may qualify if:

• The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma.

You may not qualify if:

• The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease.
• Controls:
• The subject is in good physical condition and has a stable level of consciousness;
• The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.

Sponsors & Collaborators

• Sun Yat-sen University: lead
• First People's Hospital of Foshan: collaborator

Study Sites (2)

Foshan First People's Hospital

Foshan, Guangdong, 528000, China

RECRUITING

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood

Central Study Contacts

Wei-Hua Jia, MD

CONTACT

86+020-87342327; jiawh@sysucc.org.cn

Tong-Min Wang, PhD

CONTACT

86+020-87342410; wangtm@sysucc.org.cn

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 24, 2025
• First Posted: January 30, 2025
• Study Start: January 1, 2002
• Primary Completion: June 30, 2025
• Study Completion (Estimated): December 31, 2030
• Last Updated: January 30, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)